UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Recent advances in hepatitis B research and drug development

Kanzo, 2017/04/20, Vol.58(4), pp.217-227

2017

Volltextzugriff (PDF)

Update on Hepatitis C

2017

Volltextzugriff (PDF)

Medicinal chemistry strategies toward host targeting antiviral agents

Medicinal research reviews, 2020-09, Vol.40 (5), p.1519-1557

2020

Volltextzugriff (PDF)

Epidemiology of hepatitis C virus infection in a country with universal access to direct‐acting antiviral agents: Data for designing a cost‐effective elimination policy in Spain

Journal of viral hepatitis, 2020-04, Vol.27 (4), p.360-370

2020

Volltextzugriff (PDF)

Treatment as Prevention for Hepatitis C (TraP Hep C) – a nationwide elimination programme in Iceland using direct‐acting antiviral agents

Journal of internal medicine, 2018-05, Vol.283 (5), p.500-507

2018

Volltextzugriff (PDF)

Sofosbuvir plus ribavirin in Japanese patients with chronic genotype 2 HCV infection: an open-label, phase 3 trial

Journal of viral hepatitis, 2014-11, Vol.21 (11), p.762-768

2014

Volltextzugriff (PDF)

Impact of direct‐acting antiviral regimens on mortality and morbidity outcomes in patients with chronic hepatitis c: Systematic review and meta‐analysis

Journal of viral hepatitis, 2021-05, Vol.28 (5), p.739-754

2021

Volltextzugriff (PDF)

Treating hepatitis C: current standard of care and emerging direct-acting antiviral agents

Journal of viral hepatitis, 2012-07, Vol.19 (7), p.449-464

2012

Volltextzugriff (PDF)

Long‐term follow‐up of diabetic and non‐diabetic patients with chronic hepatitis C successfully treated with direct‐acting antiviral agents

Liver international, 2021-02, Vol.41 (2), p.276-287

2021

Volltextzugriff (PDF)

Hypoglycemia associated with direct‐acting anti‐hepatitis C virus drugs: An epidemiologic surveillance study of the FDA adverse event reporting system (FAERS)

Clinical endocrinology (Oxford), 2022-05, Vol.96 (5), p.690-697

2022

Volltextzugriff (PDF)

Hepatitis C virus direct‐acting antivirals therapy impacts on extracellular vesicles microRNAs content and on their immunomodulating properties

Liver international, 2018-10, Vol.38 (10), p.1741-1750

2018

Volltextzugriff (PDF)

Sofosbuvir and Daclatasvir Combination Therapy in a Liver Transplant Recipient With Severe Recurrent Cholestatic Hepatitis C

American journal of transplantation, 2013-06, Vol.13 (6), p.1601-1605

2013

Volltextzugriff (PDF)

Prevalence and risk factors for hepatocellular carcinoma in individuals with haemophilia in the era of direct‐acting antiviral agents: A national inpatient sample study

Haemophilia : the official journal of the World Federation of Hemophilia, 2022-09, Vol.28 (5), p.769-775

2022

Volltextzugriff (PDF)

Metabolic management after sustained virologic response in elderly patients with hepatitis C virus: A multicenter study

Hepatology research, 2024-04, Vol.54 (4), p.326-335

2024

Volltextzugriff (PDF)

Efficacy of Direct‐Acting Antivirals for Chronic Hepatitis C in a Large Cohort of Older Adults in the United States

Journal of the American Geriatrics Society (JAGS), 2020-02, Vol.68 (2), p.379-387

2020

Volltextzugriff (PDF)

Peripheral neuropathy after viral eradication with direct‐acting antivirals in chronic HCV hepatitis: A prospective study

Liver international, 2021-11, Vol.41 (11), p.2611-2621

2021

Volltextzugriff (PDF)

The optimal timing of hepatitis C therapy in liver transplant‐eligible patients: Cost‐effectiveness analysis of new opportunities

Journal of viral hepatitis, 2018-07, Vol.25 (7), p.791-801

2018

Volltextzugriff (PDF)

Real‐world effectiveness of elbasvir/grazoprevir In HCV‐infected patients in the US veterans affairs healthcare system

Journal of viral hepatitis, 2018-11, Vol.25 (11), p.1270-1279

2018

Volltextzugriff (PDF)

High sustained virologic response in genotypes 3 and 6 with generic NS5A inhibitor and sofosbuvir regimens in chronic HCV in myanmar

Journal of viral hepatitis, 2019-10, Vol.26 (10), p.1186-1199

2019

Volltextzugriff (PDF)

Management of Hepatitis C Infection in children in the era of Direct‐acting Antiviral Agents

Journal of viral hepatitis, 2019-09, Vol.26 (9), p.1034-1039

2019

Volltextzugriff (PDF)

Interferon at the cellular, individual, and population level in hepatitis C virus infection: Its role in the interferon‐free treatment era

Immunological reviews, 2018-09, Vol.285 (1), p.55-71

2018

Volltextzugriff (PDF)

Low incidence of hepatitis B virus reactivation and subsequent hepatitis in patients with chronic hepatitis C receiving direct‐acting antiviral therapy

Journal of viral hepatitis, 2018-05, Vol.25 (5), p.608-611

2018

Volltextzugriff (PDF)

Involvement of portosystemic shunts in impaired improvement of liver function after direct‐acting antiviral therapies in cirrhotic patients with hepatitis C virus

Hepatology research, 2020-04, Vol.50 (4), p.512-523

2020

Volltextzugriff (PDF)

Safety and efficacy of sofosbuvir‐based direct‐acting antiviral regimens for hepatitis C virus genotype 6 in Southwest China: Real‐world experience of a retrospective study

Journal of viral hepatitis, 2019-03, Vol.26 (3), p.316-322

2019

Volltextzugriff (PDF)

Treating paediatric hepatitis C in the era of direct‐acting antiviral agents

Liver international, 2021-06, Vol.41 (6), p.1189-1200

2021

Volltextzugriff (PDF)

1 – 25 von 2.293

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(2.106)
Mit Volltextzugriff
(1.925)

Publikationsform

Artikel
(2.265)
Buchkapitel
(26)
Bücher
(1)
Berichte
(1)

Sprache

7 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Science & Technology
(2.047)
Life Sciences & Biomedicine
(2.034)
Humans
(1.588)
Hepatitis C
(1.302)
Antiviral Agents - Therapeutic Use
(1.208)
Hepatitis C, Chronic - Drug Therapy
(1.070)
Hepatitis C Virus
(1.016)
Gastroenterology & Hepatology
(858)
Antiviral Agents
(848)
Direct-Acting Antivirals
(827)
Male
(690)
Hepatitis
(667)
Female
(659)
Middle Aged
(618)
Hepacivirus - Genetics
(580)
Hepatitis C - Drug Therapy
(574)
Infectious Diseases
(483)
Interferon
(479)
Treatment Outcome
(463)
Genotype
(461)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(3)
... seit 90 Tagen
(14)

Menü

Weitere Dienste

Einstellungen

Recent advances in hepatitis B research and drug development

Update on Hepatitis C

Medicinal chemistry strategies toward host targeting antiviral agents

Epidemiology of hepatitis C virus infection in a country with universal access to direct‐acting antiviral agents: Data for designing a cost‐effective elimination policy in Spain

Treatment as Prevention for Hepatitis C (TraP Hep C) – a nationwide elimination programme in Iceland using direct‐acting antiviral agents

Sofosbuvir plus ribavirin in Japanese patients with chronic genotype 2 HCV infection: an open-label, phase 3 trial

Impact of direct‐acting antiviral regimens on mortality and morbidity outcomes in patients with chronic hepatitis c: Systematic review and meta‐analysis

Treating hepatitis C: current standard of care and emerging direct-acting antiviral agents

Long‐term follow‐up of diabetic and non‐diabetic patients with chronic hepatitis C successfully treated with direct‐acting antiviral agents

Hypoglycemia associated with direct‐acting anti‐hepatitis C virus drugs: An epidemiologic surveillance study of the FDA adverse event reporting system (FAERS)

Hepatitis C virus direct‐acting antivirals therapy impacts on extracellular vesicles microRNAs content and on their immunomodulating properties

Sofosbuvir and Daclatasvir Combination Therapy in a Liver Transplant Recipient With Severe Recurrent Cholestatic Hepatitis C

Prevalence and risk factors for hepatocellular carcinoma in individuals with haemophilia in the era of direct‐acting antiviral agents: A national inpatient sample study

Metabolic management after sustained virologic response in elderly patients with hepatitis C virus: A multicenter study

Efficacy of Direct‐Acting Antivirals for Chronic Hepatitis C in a Large Cohort of Older Adults in the United States

Peripheral neuropathy after viral eradication with direct‐acting antivirals in chronic HCV hepatitis: A prospective study

The optimal timing of hepatitis C therapy in liver transplant‐eligible patients: Cost‐effectiveness analysis of new opportunities

Real‐world effectiveness of elbasvir/grazoprevir In HCV‐infected patients in the US veterans affairs healthcare system

High sustained virologic response in genotypes 3 and 6 with generic NS5A inhibitor and sofosbuvir regimens in chronic HCV in myanmar

Management of Hepatitis C Infection in children in the era of Direct‐acting Antiviral Agents

Interferon at the cellular, individual, and population level in hepatitis C virus infection: Its role in the interferon‐free treatment era

Low incidence of hepatitis B virus reactivation and subsequent hepatitis in patients with chronic hepatitis C receiving direct‐acting antiviral therapy

Involvement of portosystemic shunts in impaired improvement of liver function after direct‐acting antiviral therapies in cirrhotic patients with hepatitis C virus

Safety and efficacy of sofosbuvir‐based direct‐acting antiviral regimens for hepatitis C virus genotype 6 in Southwest China: Real‐world experience of a retrospective study

Treating paediatric hepatitis C in the era of direct‐acting antiviral agents

Suchergebnisse filtern